Objective: To investigate the level of iodine-uptake estimated by dual-energy CT (DECT) for assessing the therapy response of non-small cell lung cancer (NSCLC) treated with chemotherapy or target therapy and to determine whether DECT criteria can evaluate the response of NSCLC treated with chemotherapy or target therapy. Methods: Thirty NSCLC patients receiving chemotherapy or target therapy and contrast-enhanced DECT scan at baseline and follow-up (at least 8 weeks and one time point) were analyzed retrospectively. Iodine-uptake level of the target lesion was measured and compared with the longest diameter and CT value of the target lesion. The 30 target lesions were evaluated by RECIST criteria, Choi criteria and dual energy CT criteria, respectively. Paired t test was used to compare the longest diameter, CT value and iodine-uptake level of the lesion at baseline and follow-up examination. Kappa statistics were used to evaluate the agreement between the results of the three response evaluation items. McNemar test was used to compare the partial response rate of DECT criteria, RECIST criteria and Choi criteria. Results: The lowering of iodine-uptake level assessed by DECT between baseline and follow-up was distinct (-10.47±23.34)%, P<0.05), while the longest diameter and CT density did not show significant change[ (-3.45±15.76)%, P>0.05; （-4.80±25.00）%, P>0.05]. DECT had better consistency with Choi criteria(kappa=0.718, P<0.05) than with RECIST （kappa=0.302, P<0.05). The partial response rate of DECT criteria had significant difference with RECIST criteria (P<0.05) and no significant difference with Choi criteria (P>0.05). Conclusions: The iodine-uptake level measured by DECT is more sensitive to evaluate the early response of NSCLC when treated with chemotherapy and target therapy than both the longest diameter and CT value. DECT criteria based on iodine uptake level and longest diameter has the potential to be a feasible method to evaluate the response of NSCLC treated with chemotherapy and target therapy.
GU Shengjia, CAO Qiqi, YAN Fuhua, YANG Wenjie
. Quantitative assessment of therapy response of non-small cell lung cancer with dual-energy CT[J]. Journal of Diagnostics Concepts & Practice, 2018
, 17(05)
: 526
-532
.
DOI: 10.16150/j.1671-2870.2018.05.009
[1] Walker S.Updates in non-small cell lung cancer[J]. Clin J Oncol Nurs,2008,12(4):587-596.
[2] NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials[J]. J Clin Oncol,2008,26(28):4617-4625.
[3] Eisenhauer EA, Therasse P, Bogaerts J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009,45(2):228-247.
[4] Bertino EM, Otterson GA.Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer[J]. Lung Cancer,2010,70(3):233-246.
[5] Lee HY, Lee KS, Ahn MJ, et al.New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy[J]. Lung Cancer,2011,73(1):63-69.
[6] Sandler AB, Schiller JH, Gray R, et al.Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab[J]. J Clin Oncol,2009,27(9):1405-1412.
[7] Johnson DH, Fehrenbacher L, Novotny WF, et al.Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,2004,22(11):2184-2191.
[8] Choi H, Charnsangavej C, Faria SC, et al.Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria[J]. J Clin Oncol,2007,25(13):1753-1759.
[9] Benjamin RS, Choi H, Macapinlac HA, et al.We should desist using RECIST, at least in GIST[J]. J Clin Oncol,2007,25(13):1760-1764.
[10] Meyer M, Hohenberger P, Apfaltrer P, et al.CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive ima-ging biomarker of clinical benefit than RECIST or Choi criteria[J]. Eur J Radiol,2013,82(6):923-928.
[11] Chandarana H, Megibow AJ, Cohen BA, et al.Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses[J]. AJR Am J Roentgenol,2011,196(6):W693-W700.
[12] Maeda H, Fang J, Inutsuka T, et al.Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications[J]. Int Immunopharmacol,2003,3(3):319-328.
[13] Uhrig M, Sedlmair M, Schlemmer HP, et al.Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases[J]. Cancer Imaging,2013,13(3):306-313.
[14] Kawai T, Shibamoto Y, Hara M, et al.Can dual-energy CT evaluate contrast enhancement of ground-glass atte-nuation? Phantom and preliminary clinical studies[J]. Acad Radiol,2011,18(6):682-689.
[15] Zhang LJ, Wu S, Wang M, et al.Quantitative dual energy CT measurements in rabbit VX2 liver tumors: Comparison to perfusion CT measurements and histopathological findings[J]. Eur J Radiol,2012,81(8):1766-1775.
[16] Klauss M, Stiller W, Pahn G, et al.Dual-energy perfusion-CT of pancreatic adenocarcinoma[J]. Eur J Radiol,2013,82(2):208-214.
[17] Ascenti G, Mileto A, Krauss B, et al.Distinguishing enhancing from nonenhancing renal masses with dual-source dual-energy CT: iodine quantification versus standard enhancement measurements[J]. Eur Radiol,2013,23(8):2288-2295.
[18] Schmid-Bindert G, Henzler T, Chu TQ, et al.Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?[J]. Eur Radiol,2012,22(1):93-103.
[19] Lee SH, Hur J, Kim YJ, et al.Additional value of dual-energy CT to differentiate between benign and malignant mediastinal tumors: an initial experience[J]. Eur J Radiol,2013,82(11):2043-2049.
[20] Moding EJ, Clark DP, Qi Y, et al.Dual-energy micro-computed tomography imaging of radiation-induced vascular changes in primary mouse sarcomas[J]. Int J Radiat Oncol Biol Phys,2013,85(5):1353-1359.
[21] Baxa J, Vondráková A, Matou?ková T, et al. Dual-phase dual-energy CT in patients with lung cancer: assessment of the additional value of iodine quantification in lymph node therapy response[J]. Eur Radiol,2014,24(8):1981-1988.
[22] Faivre S, Zappa M, Vilgrain V, et al.Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib[J]. Clin Cancer Res,2011,17(13):4504-4512.
[23] Godoy MC, Naidich DP, Marchiori E, et al.Basic principles and postprocessing techniques of dual-energy CT: illustrated by selected congenital abnormalities of the thorax[J]. J Thorac Imaging,2009,24(2):152-159.
[24] Toepker M, Moritz T, Krauss B, et al.Virtual non-contrast in second-generation, dual-energy computed tomography: reliability of attenuation values[J]. Eur J Radiol,2012,81(3):e398-e405.
